Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.77 |
| ▸ | MGLL | Q99685 | 4/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18515656 | 0.93 | PTGS1 (0.66) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL7785894 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6934781 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL3291535 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL6940132 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL24939859 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL43969 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL1574552 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779419 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 | |
| SCHEMBL8779453 | 0.88 | PTGS1 (1.00) | PTGS1PTGS2MGLLFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129063-B1 | ANTI-HER3 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2021-01-27 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148610-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120141509-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141510-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141508-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011097627-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148610-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | PTGS1 4742/4885PTGS2 4834/4885MGLL 4454/4885 |
| US-20120141510-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | PTGS1 4742/4885PTGS2 4834/4885MGLL 4454/4885 |
| US-20120141509-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | PTGS1 4742/4885PTGS2 4834/4885MGLL 4454/4885 |
| US-20120148608-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | PTGS1 4742/4885PTGS2 4834/4885MGLL 4454/4885 |
| US-20120141508-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | PTGS1 4742/4885PTGS2 4834/4885MGLL 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.